Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

The highly selective BCL2 inhibitor venetoclax achieves deep responses in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), including undetectable minimal residual disease (uMRD). We retrospectively reviewed 62 patients with CLL treated with venetoclax to investigate the...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Lew, Thomas E., Anderson, Mary Ann, Lin, Victor S., Handunnetti, Sasanka M., Came, Neil A., Blombery, Piers, Westerman, David A., Wall, Meaghan, Tam, Constantine S., Roberts, Andrew W., Seymour, John F.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2020
Assuntos:
Lymphoid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6960473/
https://ncbi.nlm.nih.gov/pubmed/31935286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000864
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares